In a National Institutes of Health (NIH)-funded study involving both mice and patients who are part of an NIH Clinical Center trial, researchers discovered that a gene, called PIEZO2, may be responsible for the powerful urge to urinate that we normally feel several times a day.
The National Institutes of Health has launched an adaptive Phase 3 clinical trial to evaluate the safety and efficacy of three immune modulator drugs in hospitalized adults with COVID-19. Some COVID-19 patients experience an immune response in which the immune system unleashes excessive amounts of proteins that trigger inflammation -- called a "cytokine storm" -- that can lead to acute respiratory distress syndrome, multiple organ failure and other life-threatening complications.
Differences in the microstructure of the nucleus accumbens (NAcc), a region in the brain that plays an important role in processing food and other reward stimuli, predict increases in indicators of obesity in children, according to a study funded by the National Institute on Drug Abuse (NIDA) and nine other institutes, all part of the National Institutes of Health. The paper, published today in the journal Proceedings of the National Academy of Sciences, is based on data from the Adolescent Brain Cognitive Development (ABCD) Study.
The National Institute of Allergy and Infectious Diseases today launched a study designed to determine whether certain approved therapies or investigational drugs in late-stage clinical development show promise against COVID-19 and merit advancement into larger clinical trials. The ACTIV-5 Big Effects Trial, which will enroll adult volunteers hospitalized with COVID-19 at as many as 40 U.S sites, is being conducted in collaboration with the NIH's public-private partnership Accelerating COVID-19 Therapeutic Innovations and Vaccines (ACTIV) program.
As public interest and expanded research in human genome editing grows, many questions remain about ethical, legal and social implications of the technology. People who are seriously ill may overestimate the benefits of early clinical trials while underestimating the risks. This makes properly understanding informed consent, the full knowledge of risks and benefits of treatments, especially important.
A clinical trial to test the safety, tolerability and efficacy of a combination treatment regimen for COVID-19 consisting of the antiviral remdesivir plus a highly concentrated solution of antibodies that neutralize SARS-CoV-2 has begun. The study is taking place in hospitalized adults with COVID-19 in the United States, Mexico and 16 other countries on five continents. NIAID is sponsoring and funding the Phase 3 trial, called Inpatient Treatment with Anti-Coronavirus Immunoglobulin, or ITAC.
A National Institutes of Health study in mice suggests that parents have an innate capacity to respond to an infant's cries for help and this capacity may serve as a foundation from which a parent learns to adjust to an infant's changing needs.
In an in-depth study of neurons grown in laboratory petri dishes, National Institutes of Health researchers discovered how neuronal synapses find the energy to support intense communications bouts thought to underlie learning and memory.
National Institutes of Health intramural researcher Harvey J. Alter, M.D., has won the 2020 Nobel Prize in Physiology or Medicine for his contributions to the discovery of the hepatitis C virus. Dr. Alter is a Senior Scholar at the NIH Clinical Center's Department of Transfusion Medicine and shares the award with Michael Houghton, Ph.D., University of Alberta, Canada, and Charles M. Rice, Ph.D., Rockefeller University, New York City.
NIH has awarded 10 grants totaling approximately $35.5 million over five years to support researchers' efforts in using tiny, bioengineered models of human tissues and organ systems to improve the design of clinical trials. One goal is to better predict which patients are most likely to benefit from an investigational therapy. The awards are administered through a new program, Clinical Trials on a Chip, which is led by NIH's National Center for Advancing Translational Sciences.